Sun Pharmaceutical is currently trading at Rs. 568.00, up by 10.00 points or 1.79% from its previous closing of Rs. 558.00 on the BSE.
The scrip opened at Rs. 565.00 and has touched a high and low of Rs. 570.95 and Rs. 557.35 respectively. So far 51,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 583.00 on 16-Sep-2013 and a 52 week low of Rs. 328.00 on 15-Nov-2012.
Last one week high and low of the scrip stood at Rs. 583.00 and Rs. 535.55 respectively. The current market cap of the company is Rs. 1, 17,638 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 25.96% and 10.39% respectively.
Sun Pharmaceutical Industries has filed four products for Abbreviated New Drug Applications and received nine approvals from the USFDA in the first quarter this fiscal. The company has now 320 ANDAs approval out of a total of 453 products filed with USFDA, and ANDAs approvals for remaining 133 products are still awaited. On a consolidated basis, the company now has 791 patent filings with 503 granted patents.
Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: